In an interview with OncLive during the 2017 State of the Science SummitTM on Genitourinary Cancers, Dr Michael Harrison, an assistant professor of medicine, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, Durham, USA, discussed results from recent clinical trials that are likely to impact the treatment options for patients with advanced renal cell carcinoma (RCC).

Exciting findings from the CABOSUN and CheckMate-214 trials for patients with advanced RCC could potentially change the way kidney cancer patients are treated.

Read the interview from OncLive here